explore -WSS

explore

author：Wikipedia 2025-10-01 21:40:05 - browse：517

Colorful illustration of scientists using computers and Artificial Intelligence technology to visualize proteins for drug development – biotech coverage from STAT — Mike Reddy for STAT

David Reese calls it a “hinge moment” — the turning point when biotech and big tech merge to attack human disease with artificial intelligence.

At Amgen, where he’s led drug research and development since 2018, Reese said this moment has finally arrived. The proof lies not only in organizational changes, such as his recent appointment as the company’s first chief technology officer, but also in Amgen’s broader push to embed AI into every aspect of the drug discovery process.

“We’re now seeing 10-fold improvements in these (AI) models every six months,” said Reese, a medical oncologist by training. He added that the quickening pace of advancement means investing in the technology is no longer optional: “It’s something we must do to have a practical, pragmatic impact on drug discovery.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： What STAT readers think about the FDA and patient advocacy

WSS

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

What affirmative action's end means to a medical student

Grail spinoff by Illumina should end disastrous merger attempt

Lupron, used to halt puberty in children, may cause lasting health problems

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Why health care costs have stayed mostly flat since 2010

focus

explore

explore

After affirmative action ruling, medical educators look to 'holistic review'

Hubble vs. James Webb telescope images: See the difference

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UpToDate has a racism problem: Dr. Stanley Goldfarb

Apple is now the first public company to be valued at $3 trillion

Prescription digital therapeutics are key to pharma’s future

Virginia high school admissions case could be legal follow

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Medical leaders decry Supreme Court decision on affirmative action

Drug cartel violence flares in western Mexico after vigilante leader's killing

hotspot

Christmas in the PICU brings some surprising joy

'Screen and refer' systems are hurting patients

Prime Medicine, Myeloid Therapeutics clash over genome

What STAT readers think about the FDA and patient advocacy

Virtual care provider acquires bankrupt Pear's prescription apps

Keeping primary care docs in field isn't impossible, says AAFP CEO

focus

explore

entertainment

focus